

1-1 By: King of Hemphill, et al. H.B. No. 428  
 1-2 (Senate Sponsor - Zaffirini)  
 1-3 (In the Senate - Received from the House April 13, 2021;  
 1-4 April 13, 2021, read first time and referred to Committee on  
 1-5 Business & Commerce; May 20, 2021, reported favorably by the  
 1-6 following vote: Yeas 9, Nays 0; May 20, 2021, sent to printer.)

1-7 COMMITTEE VOTE

	Yea	Nay	Absent	PNV
1-8	X			
1-9	X			
1-10	X			
1-11	X			
1-12	X			
1-13	X			
1-14	X			
1-15	X			
1-16	X			
1-17	X			

1-18 A BILL TO BE ENTITLED  
 1-19 AN ACT

1-20 relating to health benefit plan coverage for ovarian cancer testing  
 1-21 and screening.

1-22 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-23 SECTION 1. Section 1370.003(b), Insurance Code, is amended  
 1-24 to read as follows:

1-25 (b) Coverage required under this section includes at a  
 1-26 minimum:

1-27 (1) a CA 125 blood test; ~~and~~

1-28 (2) a conventional Pap smear screening or a screening  
 1-29 using liquid-based cytology methods, as approved by the United  
 1-30 States Food and Drug Administration, alone or in combination with a  
 1-31 test approved by the United States Food and Drug Administration for  
 1-32 the detection of the human papillomavirus; and

1-33 (3) any other test or screening approved by the United  
 1-34 States Food and Drug Administration for the detection of ovarian  
 1-35 cancer.

1-36 SECTION 2. Section 1370.003, Insurance Code, as amended by  
 1-37 this Act, applies only to a health benefit plan delivered, issued  
 1-38 for delivery, or renewed on or after January 1, 2022. A health  
 1-39 benefit plan delivered, issued for delivery, or renewed before  
 1-40 January 1, 2022, is governed by the law as it existed immediately  
 1-41 before the effective date of this Act, and that law is continued in  
 1-42 effect for that purpose.

1-43 SECTION 3. This Act takes effect September 1, 2021.

1-44 \* \* \* \* \*